91 unknown. 91 Phase 2, 14 Phase 1, 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 91 | Unknown 91 |
| Phase 1 | 14 | Unknown 14 |
| Phase 3 | 13 | Unknown 13 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma Salbutamol, Fluticason either Beclometasone or Budesonide - Asthma | Phase 2 | Unknown | Università degli Studi di Ferrara | 80 | 2024-06-18 | 2024-07-03 |
| Biological Effects of Quercetin in COPD Phase II Quercetin 1000 mg, Quercetin 500 MG, Placebo - Chronic Obstructive Pulmonary Disease, Emphysema | Phase 2 | Unknown | Temple University | 30 | 2023-11-01 | 2024-04-08 |
| Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease Bronpass Tab., Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Unknown | Hanlim Pharm. Co., Ltd. | 96 | 2023-06-01 | 2024-05-30 |
| Immunological Basis for Mepolizumab Activity in COPD Mepolizumab 100 MG - COPD | Phase 2 | Unknown | Temple University | 30 | 2023-04-01 | 2023-04-07 |
| Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma Tezepelumab, Placebo - Asthma, Allergic | Phase 2 | Unknown | McMaster University | 34 | 2023-04-01 | 2023-02-23 |
| Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults Antipyrine-benzocaine otic solution, Glycerin with Oxyquinoline Sulfate - Asthma | Phase 2 | Unknown | Global United Pharmaceutical Corporation | 50 | 2023-04-01 | 2023-02-08 |
| Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD) Benralizumab, Benralizumab placebo, Comparison (control) group; no intervention - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Unknown | Temple University | 45 | 2023-04-01 | 2023-04-07 |
| Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD Tezepelumab, Placebo - COPD, COPD Exacerbation | Phase 2 | Unknown | Asger Sverrild | 80 | 2022-10-25 | 2024-08-21 |
| A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma 610 100mg, 610 300mg, placebo - Asthma | Phase 2 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 120 | 2022-09-01 | 2022-09-06 |
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma GR1802 injection, Placebo - Asthma | Phase 2 | Unknown | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 150 | 2022-07-19 | 2024-10-15 |
| A Study of MG-K10 in Subjects With Asthma MG-K10, Placebo - Asthma | Phase 1 / Phase 2 | Unknown | Shanghai Mabgeek Biotech.Co.Ltd | 180 | 2022-07-05 | 2023-08-21 |
| Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome Ruxolitinib - Bronchiolitis Obliterans Syndrome, Hematologic Malignancy | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 50 | 2022-06-01 | 2022-10-19 |
| Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease Low-dose ibrutinib - Chronic Graft-versus-host-disease | Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 13 | 2022-04-01 | 2022-04-27 |
| A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia Orelabrutinib( lower dose), Orelabrutinib( higher dose) - Primary Immune Thrombocytopenia | Phase 2 | Unknown | Beijing InnoCare Pharma Tech Co., Ltd. | 30 | 2022-02-21 | 2023-01-12 |
| Benralizumab Initiated During Severe Asthma Attack Benralizumab 30 MG/ML [Fasenra], Placebos - Asthma Attack, Asthma | Phase 2 | Unknown | Singapore General Hospital | 128 | 2021-06-02 | 2021-07-23 |
| Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases AntiSARS-CoV-2 Serum, Placebo - Immunosuppression, Cancer | Phase 1 / Phase 2 | Unknown | Butantan Institute | 618 | 2021-05-01 | 2021-04-08 |
| Acute Exacerbations Treated With BenRAlizumab (The ABRA Study) Benralizumab, Prednisolone - Asthma, COPD | Phase 2 | Unknown | University of Oxford | 158 | 2021-03-29 | 2024-01-23 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD) placebo, Cavosonstat 5 mg, Cavosonstat 10 mg - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Unknown | GSNOR Therapeutics, Inc. | 108 | 2021-02-03 | 2020-10-23 |
| MSC for Treatment of cGVHD After Allo-HSCT Mesenchymal stem cells, Glucocorticoids, cyclosporine - Chronic Graft-versus-host Disease | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 152 | 2021-01-10 | 2020-12-31 |
| A Clinical Study on the Prevention of Mild to Moderate Intermittent Asthma With Chinese Medicine Weiyang Yuping Fang Weiyang Yuping Fang - Bronchial Asthma | Phase 2 | Unknown | Shanghai University of Traditional Chinese Medicine | 84 | 2020-10-01 | 2023-05-25 |
Showing 20 of 91. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (34) · Asthma (30) · Bronchiolitis Obliterans Syndrome (21) · Dyspnea (4) · Emphysema (4) · Inflammation (3) · Leukemia (3) · Bronchiolitis (2) · Bronchiolitis Obliterans (2) · Bronchitis (2) · Conjunctivitis, Allergic (2) · Diabetes Mellitus (2) · Graft vs Host Disease (2) · Heart Failure (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2)
Lung Diseases (91) · Respiratory Tract Diseases (91) · Bronchial Diseases (58) · Immune System Diseases (52) · Pathological Conditions, Signs and Symptoms (47) · Pathologic Processes (43) · Chronic Disease (40) · Disease Attributes (40) · Hypersensitivity, Immediate (31) · Hypersensitivity (30) · Respiratory Hypersensitivity (30) · Bronchitis (25) · Bronchiolitis (23) · Bronchiolitis Obliterans (21)
montelukast (4) · Formoterol Fumarate (3) · Glucocorticoids (3) · benralizumab (3) · Bosentan (2) · Budesonide (2) · Budesonide, Formoterol Fumarate Drug Combination (2) · Cyclosporine (2) · Exercise (2) · Interferon-gamma (2) · Quercetin (2) · Saline Solution (2) · nabiximols (2) · tezepelumab (2) · Albuterol (1)
Shanghai University of Traditional Chinese Medicine (5) · Nanfang Hospital, Southern Medical University (4) · Temple University (4) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Medical University of Vienna (2) · Technische Universität Dresden (2) · University of East Anglia (2) · Air Force Military Medical University, China (1) · Alexandria University (1) · Asger Sverrild (1) · Assaf-Harofeh Medical Center (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Baylor Research Institute (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Butantan Institute (1)
China (17) · United Kingdom (12) · United States (11) · Canada (7) · Germany (7) · South Korea (4) · Brazil (3) · Israel (3) · Austria (2) · Mexico (2) · Bangladesh (1) · Belgium (1) · Bolivia (1) · Chile (1) · Denmark (1)
Thomas Rogers, PhD (2) · Zhenhui Lu, Doctor (2) · Adelson Alves, Dr (1) · Agnieszka Brzozowska, MD, PhD (1) · Alan Miller, MD, PhD (1) · Alberto Papi, MD (1) · Andreas M Zeiher, MD (1) · Andressa Forte (1) · Andrew Wilson, MD MRCP (UK) (1) · Andrew Wilson, MD, MRCP (UK) (1) · Antonio Jimenez, Dr. (1) · Arnon Krongrad, MD (1) · Asger Sverrild, MD, PhD (1) · Badri Rickhi, MB,BS,FRCPC (1) · Birgit Assmus, MD (1)
PMID 20920189, PMID 22465313, PMID 29975735, PMID 11756187, PMID 16164444, PMID 18595980, PMID 18723437, PMID 18827155, PMID 19047234, PMID 19439742, PMID 20008582, PMID 20090057, PMID 20100768, PMID 20154234, PMID 20399493, PMID 20634158, PMID 20965785, PMID 21471175, PMID 21771118, PMID 21978929, PMID 22093109, PMID 22270499, PMID 22459779, PMID 22579125, PMID 22799753, PMID 22893340, PMID 23047831, PMID 23114233, PMID 23440689, PMID 23481463, PMID 23704092, PMID 24166905, PMID 24271095, PMID 24323036, PMID 25138330, PMID 25344148, PMID 25349312, PMID 25445859, PMID 25762226, PMID 26178642, PMID 26686407, PMID 27609406, PMID 27609408, PMID 27824606, PMID 28218239, PMID 29764875, PMID 29973284, PMID 30049223, PMID 30326954, PMID 30472801
R33AT009991 (2), 2009 (1), 2016 (1), 2017 (1), 2018 (1)